Dexcom
$73.3
503
+$0.26+0.36% Today
Statistics
Day High
73.59
Day Low
72.41
52W High
93.25
52W Low
54.11
Volume
1,180,338
Avg. Volume
6,014,872
Mkt Cap
28.59B
P/E Ratio
32.34
Dividend Yield
-
Dividend
-
Upcoming
Earnings
12FebExpected
Expected EPS
0.649411
Actual EPS
N/A
Financials
14.29%Profit Margin
Profitable8.07BRevenue
1.15BNet Income
Analyst Ratings
$83.17Average Price Target
The highest estimate is 99.00.
From 18 ratings within the last 6 months. This is not an investment recommendation.
From 18 ratings within the last 6 months. This is not an investment recommendation.
Buy 83%
Hold 11%
Sell 6%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow DXCM. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Abbott Laboratories
ABT
Mkt Cap214.96B
Medtronic
MDT
Mkt Cap116.33B
Tandem Diabetes Care
TNDM
Mkt Cap945.97M
Insulet
PODD
Mkt Cap22.03B
Senseonics
SENS
Mkt Cap287.64M
Novo Nordisk
NVO
Mkt Cap217.54B
Sanofi
SNY
Mkt Cap124.45B
Mckesson
MCK
Mkt Cap100.92B
Cardinal Health
CAH
Mkt Cap45.33B
About
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
CEO
Mr. Jacob Steven Leach
Employees
10200
Country
US
ISIN
US2521311074
Listings
0 Comments
Share your thoughts
FAQ
What is Dexcom stock price today?▼
The current price of DXCM is $73.3 USD — it has increased by +0.36% in the past 24 hours. Watch Dexcom stock price performance more closely on the chart.
What is Dexcom stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Dexcom stocks are traded under the ticker DXCM.
Is Dexcom stock price growing?▼
DXCM stock has fallen by -0.1% compared to the previous week, the month change is a +10.11% rise, over the last year Dexcom has showed a -15.62% decrease.
What is Dexcom market cap?▼
Today Dexcom has the market capitalization of 28.59B
When is the next Dexcom earnings date?▼
Dexcom is going to release the next earnings report on February 12, 2026.
What were Dexcom earnings last quarter?▼
DXCM earnings for the last quarter are 0.61 USD per share, whereas the estimation was 0.58 USD resulting in a +5.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dexcom revenue for the last year?▼
Dexcom revenue for the last year amounts to 8.07B USD.
What is Dexcom net income for the last year?▼
DXCM net income for the last year is 1.15B USD.
How many employees does Dexcom have?▼
As of February 02, 2026, the company has 10,200 employees.
In which sector is Dexcom located?▼
Dexcom operates in the Health Care sector.
When did Dexcom complete a stock split?▼
The last stock split for Dexcom was on June 13, 2022 with a ratio of 4:1.
Where is Dexcom headquartered?▼
Dexcom is headquartered in San Diego, US.